ATD-NPs was formed by three parts, including PSMA (−) prostate cancer specifically targeted part (DUP-PEG-DSPE), ROS-sensitive doxorubicin (DOX) polymeric prodrug (P(L-TK-DOX)), and the ROS generation agent (α-tocopheryl succinate, α-TOS); and this delivery system is expected to enhance PSMA (−) prostate cancer therapeutic effect, increase selective accumulation at tumor site and overcome intracellular incomplete drug release. The gene discussed is FOLH1; the disease is prostate carcinoma.